November Research Update: Food Allergy and Mental Health, Oral Allergy Syndrome - Ai kids care

November Research Update: Food Allergy and Mental Health, Oral Allergy Syndrome

Welcome to our November research update! Getting involved with research is an important way to impact food allergy treatments, education, and awareness.

This month, we are highlighting research opportunities and news on:

Note: The links below will take you to external websites.

Latest Food Allergy News

Food Allergy

Psychology Service Referrals Are Increasing for Children with Food Allergy
Over the past 10 years, anxiety related to food allergies has greatly impacted both children and their parents. But access to mental health support is often limited. A recent study reviewed 250 cases from 2013 to 2023 where children with food allergies were referred to psychological services. On average, the children were allergic to 2 foods. Over half had a severe allergic reaction in their lifetime. Food-related anxiety affected 69% of patients, while 12% faced quality of life issues. About 60% of those referred attended at least 1 psychology appointment, averaging 5.5 follow-ups within a year. Referrals for food allergy anxiety rose sharply from 2013 to 2023, with a greater increase in 2023. This highlights the growing need for expanded psychology services to support children with food allergies and their families and caregivers.

Oral Allergy Syndrome (OAS)

Anaphylm™ (Epinephrine) Sublingual Film Has Positive Results from Oral Allergy Syndrome (OAS) Challenge Study
Oral allergy syndrome (OAS) – also called pollen-food allergy syndrome (PFAS) – is a type of allergy that can cause your mouth or throat to itch when you eat certain fruits or vegetables. Recently, Aquestive Therapeutics announced positive results from its OAS study for their product, Anaphylm. Anaphylm is an under-the-tongue epinephrine film designed to treat severe allergic reactions. The study tested Anaphylm in adults with OAS, focusing on its ability to relieve symptoms like swelling and tingling caused by allergens. Results showed that Anaphylm resolved symptoms quickly, with complete relief in 12 minutes. This response time is much faster than the initial 74 minutes without Anaphylm. The study met all primary and secondary goals, and Anaphylm was well-tolerated with only mild or moderate side effects. Aquestive plans to submit Anaphylm for FDA approval in early 2025 and hopes to launch the product in 2026. Anaphylm could offer another alternative to current epinephrine treatments for severe allergic reactions.

Stay in the loop – get news and research updates straight to your inbox with our e-newsletters.

SIGN ME UP FOR UPDATES!




Source link

Leave a Comment